CAM
DNLI icon

ClariVest Asset Management’s Denali Therapeutics DNLI Stock Holding History

ClariVest Asset Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$533K Hold
22,964
– – 0.05% 345
2024
Q2 		$533K Sell
22,964
-24,784
-52% -$476K 0.05% 345
2024
Q1 		$980K Buy
47,748
+7,568
+19% +$142K 0.1% 272
2023
Q4 		$862K Sell
40,180
-2,721
-6% -$53.9K 0.05% 286
2023
Q3 		$885K Buy
42,901
+38
+0.1% +$964 0.05% 256
2023
Q2 		$1.26M Sell
42,863
-6,404
-13% -$180K 0.06% 198
2023
Q1 		$1.14M Buy
49,267
+39
+0.1% +$1.07K 0.05% 268
2022
Q4 		$1.37M Sell
49,228
-152
-0.3% -$4.52K 0.07% 230
2022
Q3 		$1.51M Sell
49,380
-5,258
-10% -$171K 0.07% 196
2022
Q2 		$1.61M Sell
54,638
-11,000
-17% -$288K 0.07% 216
2022
Q1 		$2.11M Hold
65,638
– – 0.08% 208
2021
Q4 		$2.93M Sell
65,638
-5,828
-8% -$276K 0.09% 200
2021
Q3 		$3.61M Sell
71,466
-3,779
-5% -$213K 0.12% 178
2021
Q2 		$5.9M Buy
75,245
+58,039
+337% +$3.59M 0.2% 103
2021
Q1 		$982K Buy
17,206
+473
+3% +$31.7K 0.03% 289
2020
Q4 		$1.4M Sell
16,733
-22,764
-58% -$1.38M 0.05% 237
2020
Q3 		$1.41M Buy
39,497
+8,158
+26% +$246K 0.05% 268
2020
Q2 		$757K Buy
+31,339
New +$737K 0.02% 351

Other funds holding DNLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

ClariVest Asset Management's DNLI Position: Q3 2024 in Review

ClariVest Asset Management held its Denali Therapeutics (DNLI) position steady in Q3 2024 at 22,964 shares worth $533K. The position accounts for 0.05% of the portfolio, ranked #345.

ClariVest Asset Management first reported a position in DNLI in Q2 2020 and has held it in 18 quarters since. The position peaked at $5.9M in Q2 2021. 217 funds tracked by Wall St. Rank hold DNLI as of Q3 2024.

  • ClariVest Asset Management held 22,964 shares of Denali Therapeutics worth $533K as of Q3 2024.
  • ClariVest Asset Management left its Denali Therapeutics share count unchanged in Q3 2024.
  • Denali Therapeutics made up 0.05% of ClariVest Asset Management's portfolio in Q3 2024, its #345 holding.
  • ClariVest Asset Management first reported a position in Denali Therapeutics in Q2 2020 and has held it in 18 quarters since.
  • ClariVest Asset Management's Denali Therapeutics position peaked at $5.9M in Q2 2021.
  • 217 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2024.

Based on ClariVest Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.